|
Name: JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole)
Type: Synthetic cannabinoid
AKA: JWH-200
![JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) image](https://grammasearch.com/dev/v2/aiimages/jwh-200_%281-%5B2-%284-morpholinyl%29ethyl%5D-3-%281-naphthoyl%29indole%29.png)
|
|
II. Natural Derivative
Synthetic substance, no natural derivative
 |
|
III. Chemical Profile (IUPAC name)
![JWH-200 (1-[2-(4-Morpholinyl)ethyl]-3-(1-naphthoyl)indole) image](/dev/v2/pages/pubchem_images/10482430.png)
|
|
IV. History
JWH-200 is a synthetic cannabinoid developed by Dr. John W. Huffman in the 1990s. It is part of a series of compounds designed to study the endocannabinoid system. JWH-200 mimics the effects of THC but with varying potency and duration. It has been found in recreational drug markets and is subject to regulation due to its potential for abuse and adverse effects.
|
|
V. Legal Information
JWH-200, a synthetic cannabinoid, is regulated under analog laws in the US due to its similarity to other controlled substances. It is subject to restrictions reflecting concerns about synthetic cannabinoids' effects and abuse potential. Globally, JWH-200 faces increasing restrictions as part of broader efforts to control new psychoactive substances.
US Federal Schedule - I
Schedule I drugs, substances, or chemicals are defined as drugs with no currently accepted medical use and a high potential for abuse. Some examples of Schedule I drugs are: heroin, lysergic acid diethylamide (LSD), marijuana (cannabis), 3,4-methylenedioxymethamphetamine (ecstasy), methaqualone, and peyote.
Key US Federal Policies:
Controlled Substances Act. Public Law: Public Law 91-513 (text can be found on GovInfo) (https://www.dea.gov/drug-information/csa). Date enacted: October 27, 1970.
|
|
VI. Physical Effects
JWH-200, a synthetic cannabinoid, produces psychoactive effects similar to THC. As an upper, it can cause euphoria and altered perception. Short-term effects include increased heart rate and anxiety, while long-term use may lead to severe mental health issues. Overdose risks involve acute psychosis and cardiovascular problems. Safe use is difficult due to potency variability. Recent research highlights its high potency and associated risks, stressing the need for regulation.  |
|
VII. Psychological Effects
JWH-200, a synthetic cannabinoid, affects the endocannabinoid system, causing mood alteration and cognitive effects. Psychological effects include euphoria, anxiety, and hallucinations. Effects last several hours, with risks of severe mental health issues and dependence. Research focuses on its safety and psychological impact.
 |
|
VIII. Culture
JWH-200 is a synthetic cannabinoid with effects similar to THC, classifying it as a downer. Short-term use induces euphoria and relaxation, while long-term use can lead to cognitive impairment and psychological dependence. Overdose risks include severe anxiety, hallucinations, and cardiovascular issues. Safe dosages are not well-established, with lower doses advised. Recent research highlights its high abuse potential and associated health risks. Physical effects include red eyes, dry mouth, and altered mental state.
 |